Special Issue

Current Research on Pharmacogenomics

Message from the Guest Editor

Genetic variation has long been considered an important contributor to inter-individual variability in drug response. Many common variants in genes that are involved in drug absorption, distribution, metabolism. and excretion (ADME) are shown to decrease or increase enzyme activity and, as a result, may affect drug efficacy and induce drug toxicity. However, even with strong scientific evidence supporting the pharmacogenetic associations of these variants, their clinical implementation remains limited. Over the last 20 years, the development of sequencing technologies has revealed hundreds of thousands of novel and rare variants in pharmacogenes. It provides opportunities that help us to identify novel pharmacogenomic associations and profile pharmacogenomic variations between individuals and populations, but also poses significant challenges regarding variant interpretation and clinical implementation. This Special Issue aims to present readers with updated research and expert opinions that addresses the current opportunities and challenges in the pharmacogenomics field.

Guest Editor

Dr. Yitian Zhou

Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden

Deadline for manuscript submissions

closed (15 February 2024)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/184659

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

